Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Salman Ghiasuddin

Interventional Cardiology Newburyport, MA Medical Doctor

NPI 1467446120 CMS profile 111070

7 Henry Graf Road, Newburyport, MA 01950

Open in the dashboard

General payments

$13,624

371 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Salman Ghiasuddin of Newburyport, MA is reported in the CMS Open Payments database as having received $13,624 across 371 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $813 30
2024 General $3,262 73
2023 General $1,422 63
2022 General $1,105 53
2021 General $2,083 54
2020 General $1,404 33
2019 General $3,535 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Salman Ghiasuddin
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Salman Ghiasuddin were reported at $813. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Salman Ghiasuddin Interventional Cardiology median Middle half National median
2019 $3,535 $1,097 $329–$3,048 $163
2020 $1,404 $473 $161–$1,480 $114
2021 $2,083 $677 $233–$1,827 $132
2022 $1,105 $978 $333–$2,724 $149
2023 $1,422 $1,136 $382–$2,986 $160
2024 $3,262 $1,181 $395–$3,326 $164
2025 $813 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $2,481 20 payments
  2. Penumbra, Inc. $2,027 6 payments
  3. Pfizer Inc. $1,549 69 payments
  4. Boston Scientific Corporation $1,440 11 payments
  5. Cardiovascular Systems Inc. $811 5 payments
  6. E.R. Squibb & Sons, L.L.C. $735 39 payments
  7. Novartis Pharmaceuticals Corporation $659 42 payments
  8. Janssen Pharmaceuticals, Inc $629 36 payments
  9. AstraZeneca Pharmaceuticals LP $604 29 payments
  10. Amgen Inc. $572 23 payments
  11. Other $2,116 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,974 354 payments
  2. Travel and Lodging $4,628 15 payments
  3. Education $22 2 payments
Products named General payments · program years 2019–2025
  1. CoreValve Evolut $2,384 17 payments
  2. RUBY Coil $1,922 5 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $1,144 54 payments
  4. Coronary Orbital Atherectomy System $811 5 payments
  5. VYNDAQEL $743 31 payments
  6. XARELTO $629 36 payments
  7. ANGIOJET Angioplasty $600 2 payments
  8. ANGIOJET Pain Management $600 2 payments
  9. Repatha $517 20 payments
  10. ELIQUIS Cardiovascular $455 23 payments
  11. Other $5,489 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

6,620

Median for Cardiology: 2,533

Drug cost

$1,492,640

Median for Cardiology: $485,213

Branded share of claims

36.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 782 $901,032
Xarelto Rivaroxaban Brand 233 $274,731
Repatha Sureclick Evolocumab Brand 67 $71,013
Entresto Sacubitril/Valsartan Brand 39 $57,769
Jardiance Empagliflozin Brand 57 $38,020
Praluent Pen Alirocumab Brand 36 $31,842
Brilinta Ticagrelor Brand 13 $14,457
Metoprolol Succinate Generic 648 $11,063
Farxiga Dapagliflozin Propanediol Brand 12 $10,545
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 557 $9,832

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$488,920

Of which drugs: $2,476

Medicare patients

1,181

Average age 77

Services billed

5,251

619 women, 562 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Arthritis 54%
Atrial fibrillation 41%
Diabetes 31%
Heart failure 27%
Chronic kidney disease 26%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 77 290 $2,333
Injection, aminophyllin, up to 250 mg J0280 Office 22 22 $143

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $172
  • E.R. Squibb & Sons, L.L.C. $48
$221 782 —
Repatha
  • Amgen Inc. $211
$211 67 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $143
$143 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $138
$138 12 —
VYNDAQEL
  • PFIZER INC. $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

371 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record